Open AccessA prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Author(s) -
Richa Manwani,
Oliver Cohen,
Faye Sharpley,
Shameem Mahmood,
Sajitha Sachchithanantham,
Darren Foard,
Helen J. Lachmann,
Cristina Quarta,
Marianna Fontana,
Julian D. Gillmore,
Carol Whelan,
Philip N. Hawkins,
Ashutosh Wechalekar
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000834
Subject(s) - bortezomib , amyloidosis , al amyloidosis , observational study , medicine , multiple myeloma , oncology , immunoglobulin light chain , immunology , antibody
This article reports the largest series of patients with systemic AL amyloidosis to date treated with first-line bortezomib. With relatively mature follow-up, the data indicate the importance of a stringent dFLC response (difference in involved and uninvolved light chains) as a predictor of prolonged response.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom